The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Bomedemstat for high-risk myelofibrosis
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, discusses the ongoing Phase I/IIa study (NCT03136185) of IMG-7289-CTP-102 (bomedemstat), a first in class LSD1 inhibitor in patients with myelofibrosis. Dr Yacoub highlights that the agent could be disease-modifying, as shown by good objective response rates as defined by reduction of spleen volume, and deep symptom responses in patients. He goes on to discuss the tolerability of bomedemstat, in which no serious adverse events have been observed. With clear clinical activity in patients with high-risk mutations, bomedemstat has potential as a novel agent for first-line therapy in patients with high-risk myelofibrosis. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
